Abstract
RAS oncogenes have been identified in about 30% of all human cancers, particularly in 90% of human pancreatic cancers, 50% of colorectal tumors, and 30% of lung cancers. RAS is a central switch for many signal transduction pathways. The RAS proteins undergo three major posttranslational modification steps to become fully functional: prenylation (farnesylation or geranylgeranylation) of the cysteine residue of the CAAX of the RAS C-terminus (C, cysteine, A, aliphatic amino acid; X, Ser, Met, Glu, and Leu), endoproteolysis to remove the AAX amino acid sequence, and methylation of the newly formed prenylated cysteine C-terminus. It is hypothesized that any of these three steps could be an interference point for targeting RAS signaling to block the growth of the mutant RAS-dominant cancer cells. In the last decade, intensive efforts have been directed to target the prenylation of RAS, resulting in many RAS farnesylation inhibitors, which are in the clinical trials with mixed results. On the other hand, both recent chemical genetic and traditional genetic studies demonstrate that targeting two prenylation-dependent modification enzymes, RAS endoprotease and methyltransferase, might be two additional targets in killing mutant RAS-dependent cancer cells. This mini-review discusses the implications of both RAS endoprotease and methyltransferase as anticancer targets and their respective inhibitors as anticancer agents in cancer therapy.
Keywords: RAS, endoprotease, farnesyltransferase, methyltransferase, anticancer target, inhibitor
Current Signal Transduction Therapy
Title: Targeting Prenylated RAS Modifying Enzymes in Cancer Cells
Volume: 1 Issue: 3
Author(s): Yulong L. Chen
Affiliation:
Keywords: RAS, endoprotease, farnesyltransferase, methyltransferase, anticancer target, inhibitor
Abstract: RAS oncogenes have been identified in about 30% of all human cancers, particularly in 90% of human pancreatic cancers, 50% of colorectal tumors, and 30% of lung cancers. RAS is a central switch for many signal transduction pathways. The RAS proteins undergo three major posttranslational modification steps to become fully functional: prenylation (farnesylation or geranylgeranylation) of the cysteine residue of the CAAX of the RAS C-terminus (C, cysteine, A, aliphatic amino acid; X, Ser, Met, Glu, and Leu), endoproteolysis to remove the AAX amino acid sequence, and methylation of the newly formed prenylated cysteine C-terminus. It is hypothesized that any of these three steps could be an interference point for targeting RAS signaling to block the growth of the mutant RAS-dominant cancer cells. In the last decade, intensive efforts have been directed to target the prenylation of RAS, resulting in many RAS farnesylation inhibitors, which are in the clinical trials with mixed results. On the other hand, both recent chemical genetic and traditional genetic studies demonstrate that targeting two prenylation-dependent modification enzymes, RAS endoprotease and methyltransferase, might be two additional targets in killing mutant RAS-dependent cancer cells. This mini-review discusses the implications of both RAS endoprotease and methyltransferase as anticancer targets and their respective inhibitors as anticancer agents in cancer therapy.
Export Options
About this article
Cite this article as:
Chen L. Yulong, Targeting Prenylated RAS Modifying Enzymes in Cancer Cells, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226897
DOI https://dx.doi.org/10.2174/157436206778226897 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
Call for Papers in Thematic Issues
Metabolism in Inflammation-Induced Cancer
We will talk about the primary mechanisms and principles of inflammation-induced cancer based on the most recent research findings and our understanding of the tumor development process, with an emphasis on the crosstalk between metabolism and inflammation-induced cancer. The regulatory mechanisms of T cell subpopulation differentiation, the regulatory function of ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Editorial [Hot Topic: Recent Advances in Understanding of Cigarette Smoke Free Radicals and Their Relationship to Smoking Related Diseases (Guest Editors: Chuan Liu and Kevin McAdam)]
Mini-Reviews in Organic Chemistry Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer
Clinical Cancer Drugs Functional Non-Synonymous Polymorphisms Prediction Methods: Current Approaches and Future Developments
Current Medicinal Chemistry Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews Cannabinoids Receptors in COVID-19: Perpetrators and Victims
Current Medicinal Chemistry Reversal of Multidrug Resistance by the P-Glycoprotein Modulator, LY335979, from the Bench to the Clinic
Current Medicinal Chemistry Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Application of Biological Study for Met Expression to Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Lanoconazole and Its Related Optically Active Compound NND-502: Novel Antifungal Imidazoles with a Ketene Dithioacetal Structure
Current Medicinal Chemistry - Anti-Infective Agents Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery